Last update 07 Nov 2024

SGB-9768

Overview

Basic Info

Drug Type
siRNA
Synonyms
SGB 9768
Target
C3
Mechanism
C3 inhibitors(Complement C3 inhibitors)
Therapeutic Areas
Immune System DiseasesUrogenital DiseasesOther Diseases
Active Indication
C3 glomerulopathyGlomerulonephritis, IGAGlomerulonephritis, Membranoproliferative+ [1]
Inactive Indication-
Originator Organization
Sanegene Bio (Suzhou) Co., Ltd.Sanegene Bio (Suzhou) Co., Ltd.
Active Organization
Sanegene Bio (Suzhou) Co., Ltd.Sanegene Bio (Suzhou) Co., Ltd.
Inactive Organization-
Drug Highest PhasePhase 1
First Approval Date-
Regulation-
Login to view timeline

Related

3
Clinical Trials associated with SGB-9768
CTR20242373 / RecruitingPhase 1
在中国健康受试者中评价单次皮下给药SGB-9768注射液的安全性、耐受性、药代动力学以及药效学特征的I期临床试验
[Translation] A Phase I clinical trial to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of a single subcutaneous dose of SGB-9768 injection in healthy Chinese subjects
NCT06501573 / Not yet recruitingPhase 1
A Phase 1, Randomized, Double-blind, Placebo-controlled Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneously Administered SGB-9768 in Healthy Volunteers
ACTRN12624000054516 / RecruitingPhase 1
A Phase 1, Randomized, Double-blind, Placebo-Controlled Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneously Administered SGB-9768 in Healthy Volunteers
100 Clinical Results associated with SGB-9768
Login to view more data
100 Translational Medicine associated with SGB-9768
Login to view more data
100 Patents (Medical) associated with SGB-9768
Login to view more data
100 Deals associated with SGB-9768
Login to view more data

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
C3 glomerulopathyPhase 1
CN
Sanegene Bio (Suzhou) Co., Ltd.Sanegene Bio (Suzhou) Co., Ltd.
18 Jul 2024
Glomerulonephritis, IGAPhase 1
CN
Sanegene Bio (Suzhou) Co., Ltd.Sanegene Bio (Suzhou) Co., Ltd.
18 Jul 2024
Glomerulonephritis, MembranoproliferativePhase 1
CN
Sanegene Bio (Suzhou) Co., Ltd.Sanegene Bio (Suzhou) Co., Ltd.
18 Jul 2024
Immune System DiseasesIND Approval
NZ
Sanegene Bio (Suzhou) Co., Ltd.Sanegene Bio (Suzhou) Co., Ltd.
27 Feb 2024
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date

No Data

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
login
or
view full example data
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
login
or
view full example data
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
login
or
view full example data
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
login
or
view full example data
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free